Resolutions at the annual general meeting of Nuevolution AB (publ)

28 May 2018

At the annual general meeting of Nuevolution AB (publ) on 28 May 2018, the following resolutions were resolved.

Approval of the annual report, appropriation of result and discharge from liability

The annual general meeting resolved to adopt the income statement and balance sheet for Nuevolution and the group for the financial year 1 July-31 December 2017. Furthermore, it was resolved that the company’s results shall be carried forward and thus no dividend will be distributed. The annual general meeting also resolved to discharge the board members and the managing director from liability.

Number of board members and auditors, election of board members and auditors and fees to the board members and auditors

The annual general meeting resolved that the number of board members, as appointed by the annual general meeting, should be five with no deputies. Stig Løkke Pedersen, Søren Lemonius, Lars Henriksson, Jutta Heim and Jeanette Wood were re-elected as members of the board. Stig Løkke Pedersen was re-elected as chairman of the board.

The annual general meeting resolved that the number of auditors shall be one with no deputies. Ernst & Young Aktiebolag was re-elected as the company’s auditor, with the request that authorized auditor Beata Lihammar will be auditor in charge, for the period up to the end of the next annual general meeting.

The annual general meeting resolved that the remuneration to the board of directors shall be paid in a total amount of SEK 1,320,000, to be allocated as follows. The chairman shall receive

SEK 400,000, and other members, who are not employed by the company, shall receive

SEK 200,000 each. The remuneration for work in the committees of the board of directors shall be distributed with SEK 50,000 to the chairman of the audit committee and SEK 25,000 to the other member, SEK 30,000 to the chairman of the remuneration committee and SEK 15,000 to the other member. Remuneration to the auditors shall be paid in accordance with approved invoices within the auditors’ quotation.

Resolution regarding the nomination committee

The annual general meeting resolved to approve the proposed principles for appointment of the nomination committee until the general meeting resolves otherwise.

Resolution regarding authorization for the board of directors to resolve to issue new shares, warrants and convertibles

The annual general meeting resolved, in accordance with the board’s proposal, to authorize the board of directors, for the period up to the next annual general meeting, to adopt decisions, whether on one or several occasions and whether with or without pre-emption rights for the shareholders, to issue new shares and warrants and/or convertibles with a right to subscribe/convert to shares. Issuance of shares, warrants and/or convertibles may be possible to an amount, after any subscription/conversion, not exceeding 20 per cent of the total number of outstanding shares in the company before utilization of the authorization. Issues may be made with or without provisions concerning non-cash consideration, set-off or other provisions. The purpose of the authorization is to provide the board with flexibility in its work to secure that the company, in a suitable way, can be provided with capital for the financing of the business, to enable a broadening of the ownership of the company, increase the liquidity in, and trading volume of, the share and to be used in strategic partnerships.

For more information, please contact: 

Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987

Henrik D. Simonsen, CFO
Phone: +45 3913 0947

Information about Nuevolution AB (publ) 

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information was released for publication at 17.30 CET on 28 May 2018.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links